Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
54.75B
Market cap54.75B
Price-Earnings ratio
-235.35
Price-Earnings ratio-235.35
Dividend yield
Dividend yield
Average volume
1.46M
Average volume1.46M
High today
$326.03
High today$326.03
Low today
$310.95
Low today$310.95
Open price
$321.59
Open price$321.59
Volume
1.57M
Volume1.57M
52 Week high
$326.03
52 Week high$326.03
52 Week low
$149.38
52 Week low$149.38

Stock Snapshot

With a market cap of 54.75B, Natera(NTRA) trades at $320.90. The stock has a price-to-earnings ratio of -235.35.

On 2026-08-10, Natera(NTRA) stock moved within a range of $310.95 to $326.03. With shares now at $320.90, the stock is trading +3.2% above its intraday low and -1.6% below the session's peak.

Trading activity shows a volume of 1.57M, compared to an average daily volume of 1.46M.

Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $326.03 and a low of $149.38.

Over the past 52 weeks, Natera(NTRA) stock has traded between a high of $326.03 and a low of $149.38.

NTRA News

TipRanks 6h
Natera price target raised to $355 from $310 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Natera (NTRA) to $355 from $310 and keeps an Overweight rating on the shares. Unlock powerful investing tools...

Nasdaq 8h
Natera Reaches Analyst Target Price

In recent trading, shares of Natera Inc (Symbol: NTRA) have crossed above the average analyst 12-month target price of $100.75, changing hands for $105.29/share...

Natera Reaches Analyst Target Price
Simply Wall St 1d
Natera Is Up 20.3% After Raising 2026 Guidance And Expanding Signatera’s Oncology Reach

In early August 2026, Natera reported second-quarter revenue of US$752.75 million with higher testing volumes and narrower losses, raised full-year 2026 revenue...

Natera Is Up 20.3% After Raising 2026 Guidance And Expanding Signatera’s Oncology Reach

Analyst ratings

88%

of 24 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More NTRA News

Nasdaq 2d
Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead.

Key Points Billionaire investor Stanley Druckenmiller has a long track record of success. His Duquesne Family office only holds one "Magnificent Seven" stock,...

Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead.
Simply Wall St 4d
Natera Posted Strong Q2 Results, Is The Stock Fully Priced?

Natera (NTRA) is back in focus after reporting Q2 2026 earnings on August 6, with revenue of US$752.75 million and a narrower net loss, alongside fresh regulato...

Natera Posted Strong Q2 Results, Is The Stock Fully Priced?
Nasdaq 4d
Natera Q2 Loss Narrows As Revenue Jumps; Raises FY26 Revenue Outlook

(RTTNews) - Natera Inc. (NTRA) on Thursday reported a narrower second-quarter loss as revenue surged 38% on higher testing volumes and pricing improvements. The...

Natera Q2 Loss Narrows As Revenue Jumps; Raises FY26 Revenue Outlook
TipRanks 4d
Natera’s SCORE-NHL Study Builds Long-Term Value in Lymphoma Monitoring

Natera Inc. (NTRA) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...

Nasdaq 5d
Natera Files For Japan PMDA Approval Of Signatera Test In Bladder Cancer

(RTTNews) - Natera, Inc. (NTRA), a genetic testing company said on Wednesday that it has filed for approval in Japan to use its Signatera test as a companion di...

Natera Files For Japan PMDA Approval Of Signatera Test In Bladder Cancer
The Motley Fool 6d
Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?

It can pay to track what the big investors on Wall Street are trading in quarterly 13-F filings. This quarter, legendary hedge fund manager Stanley Druckenmille...

Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy?

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.